Key | % Net Assets |
---|---|
Pfizer Inc. | 7.5% |
Johnson & Johnson | 7.0% |
Novartis AG | 5.7% |
GlaxoSmithKline PLC | 5.6% |
Other | 74.2% |
Name | % Net Assets |
---|---|
Pfizer Inc. | 7.5% |
Johnson & Johnson | 7.0% |
Novartis AG | 5.7% |
GlaxoSmithKline PLC | 5.6% |
Roche Holding AG | 5.6% |
Roche Holding AG | 4.0% |
Merck & Co. Inc. | 3.8% |
Amgen Inc. | 3.6% |
Schering-Plough Corp. | 3.4% |
AstraZeneca PLC | 3.0% |
No asset data available.
Date | 15-Jan-2008 |
---|---|
NAV | 74.10p |
Currency | GBP |
Change | 0.39p |
% | 0.53% |
YTD change | 74.10p |
YTD % | n/a |
Fund Inception | 15/07/2002 |
---|---|
Fund Manager | Anne Marieke Ezendam |
TER | - |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | -0.09 |
You are here: research